Quality-adjusted life years among people who inject drugs in a needle syringe program in Sweden

[1] Degenhardt L(2016)Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013 The Lancet Infectious Diseases 16 1385-1398

[2] Charlson F(2016)Alcohol and Drug Use Collaborators, 2018 The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016 Lancet Psychiatry 5 987-1012

[3] Stanaway J(2014)Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions PLoS ONE 9 e104515-563

[4] Larney S(2018)Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: Findings from a Cochrane Review and meta-analysis Addiction 113 545-e1220

[5] Alexander LT(2017)Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: A systematic review The Lancet Global Health 5 e1208-52

[6] Hickman M(2014)Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness International Journal of Drug Policy 25 34-93

[7] Cowie B(2020)A qualitative study of facilitators and barriers to participate in a needle exchange program for women who inject drugs Harm Reduction Journal 17 84-1532

[8] Hall WD(2019)Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs International Journal of Drug Policy 66 87-2215

[9] Strang J(2005)Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D Quality of Life Research 14 1523-1111

[10] Whiteford H(2006)Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St Petersburg Russia AIDS 20 2207-25

[1] Degenhardt L(2016)Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013 The Lancet Infectious Diseases 16 1385-1398

[2] Charlson F(2016)Alcohol and Drug Use Collaborators, 2018 The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016 Lancet Psychiatry 5 987-1012

[3] Stanaway J(2014)Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions PLoS ONE 9 e104515-563

[4] Larney S(2018)Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: Findings from a Cochrane Review and meta-analysis Addiction 113 545-e1220

[5] Alexander LT(2017)Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: A systematic review The Lancet Global Health 5 e1208-52

[6] Hickman M(2014)Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness International Journal of Drug Policy 25 34-93

[7] Cowie B(2020)A qualitative study of facilitators and barriers to participate in a needle exchange program for women who inject drugs Harm Reduction Journal 17 84-1532

[8] Hall WD(2019)Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs International Journal of Drug Policy 66 87-2215

[9] Strang J(2005)Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D Quality of Life Research 14 1523-1111

[10] Whiteford H(2006)Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St Petersburg Russia AIDS 20 2207-25